Emerging pharmacological strategies in lipoprotein(a) reduction.

Q3 Medicine

Baylor University Medical Center Proceedings Pub Date : 2025-07-09 eCollection Date: 2025-01-01 DOI:10.1080/08998280.2025.2524791

Taha Mansoor, Mahmoud Ismayl, Sachin Parikh, Vijay Nambi, Salim S Virani, Anurag Mehta, Xiaoming Jia, Abdul Mannan Khan Minhas

{"title":"Emerging pharmacological strategies in lipoprotein(a) reduction.","authors":"Taha Mansoor, Mahmoud Ismayl, Sachin Parikh, Vijay Nambi, Salim S Virani, Anurag Mehta, Xiaoming Jia, Abdul Mannan Khan Minhas","doi":"10.1080/08998280.2025.2524791","DOIUrl":null,"url":null,"abstract":"Background: Lipoprotein(a) (Lp(a)) is an low-density lipoprotein (LDL)-like particle whose elevation is considered a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. Currently, there are no published clinical trials showing whether Lp(a) lowering in conjunction with optimal LDL cholesterol control reduces ASCVD risk.Methods: Clinicaltrials.gov, an online database for clinical research studies, was used to identify ongoing clinical trials studying targeted Lp(a) lowering pharmacotherapy as of May 2025. Twelve clinical studies met the criteria and were included in this summary.Results: The three large, multicenter phase 3 outcome trials evaluating clinical cardiovascular disease endpoints of major adverse cardiac event (MACE) are Lp(a)HORIZON (NCT04023552), OCEAN(a) (NCT05581303), and ACCLAIM-Lpa(a) (NCT06292013), which investigate pelacarsen, olpasiran, and lepodisiran, respectively. Other phase 2 and phase 3 trials are also under way.Conclusion: Results from upcoming trials will inform us whether Lp(a) reductions translate to improved cardiovascular clinical outcomes.","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 5","pages":"783-786"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351719/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2025.2524791","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lipoprotein(a) (Lp(a)) is an low-density lipoprotein (LDL)-like particle whose elevation is considered a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. Currently, there are no published clinical trials showing whether Lp(a) lowering in conjunction with optimal LDL cholesterol control reduces ASCVD risk.

Methods: Clinicaltrials.gov, an online database for clinical research studies, was used to identify ongoing clinical trials studying targeted Lp(a) lowering pharmacotherapy as of May 2025. Twelve clinical studies met the criteria and were included in this summary.

Results: The three large, multicenter phase 3 outcome trials evaluating clinical cardiovascular disease endpoints of major adverse cardiac event (MACE) are Lp(a)HORIZON (NCT04023552), OCEAN(a) (NCT05581303), and ACCLAIM-Lpa(a) (NCT06292013), which investigate pelacarsen, olpasiran, and lepodisiran, respectively. Other phase 2 and phase 3 trials are also under way.

Conclusion: Results from upcoming trials will inform us whether Lp(a) reductions translate to improved cardiovascular clinical outcomes.

查看原文本刊更多论文

脂蛋白(a)减少的新药理学策略。

背景：脂蛋白(a) （Lp(a)）是一种低密度脂蛋白（LDL）样颗粒，其升高被认为是动脉粥样硬化性心血管疾病（ASCVD）和钙化性主动脉瓣狭窄的因果危险因素。目前，没有发表的临床试验表明Lp(a)降低与最佳LDL胆固醇控制是否能降低ASCVD风险。方法：临床研究在线数据库Clinicaltrials.gov用于确定截至2025年5月正在进行的靶向Lp(a)降低药物治疗的临床试验。12项临床研究符合标准并纳入本摘要。结果：三个评估主要不良心脏事件（MACE）临床心血管疾病终点的大型多中心3期结局试验是Lp(a)HORIZON （NCT04023552）、OCEAN(a) （NCT05581303）和ACCLAIM-Lpa(a) (NCT06292013)，分别研究pelacarsen、olpasiran和lepodisiran。其他2期和3期试验也在进行中。结论：即将进行的试验结果将告诉我们Lp(a)的降低是否转化为心血管临床结果的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Baylor University Medical Center Proceedings Medicine-Medicine (all)

CiteScore

1.30

自引率

0.00%

发文量

245